Multi-omics pan-cancer study of SPTBN2 and its value as a potential therapeutic target in pancreatic cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.SPTBN2 gene overexpression is linked to poor prognosis in pancreatic cancer (PAAD) and other cancers. SPTBN2 may serve as a prognostic biomarker and immunotherapy target, influencing immune cell levels in PAAD.
Area Of Science
- Oncology
- Genetics
- Immunology
Background
- SPTBN2 gene's role in tumorigenesis is largely unknown.
- Its prognostic value in pan-cancer, particularly pancreatic cancer (PAAD), requires investigation.
Purpose Of The Study
- To explore the prognostic value and biological mechanisms of SPTBN2 in pan-cancer, with a focus on PAAD.
- To evaluate SPTBN2 as a potential biomarker for prognosis and therapeutic response in PAAD.
Main Methods
- Multi-omics data analysis across pan-cancer databases.
- Investigation of SPTBN2 expression, mutations, methylation, and survival correlations.
- Immunoassay and enrichment analysis to determine functional roles and immune pathway involvement.
Main Results
- SPTBN2 is upregulated in most tumor tissues and linked to poorer survival in PAAD and kidney renal clear cell carcinoma.
- SPTBN2 acts as an independent prognostic factor in PAAD, with its expression affected by mutations and methylation.
- SPTBN2 may predict therapeutic response and influence immunotherapy efficacy by modulating CD8+ T cells and neutrophils in PAAD.
Conclusions
- SPTBN2 is a potential prognostic biomarker and immunotherapy target in PAAD.
- SPTBN2's role in PAAD development involves immune pathways.
- Further research into SPTBN2 is warranted for its clinical application in PAAD.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
